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Abstract
PDGF is an important polypeptide growth factor that plays an essential role during early vertebrate development and 
is associated with tissue repair and wound healing in the adult vertebrate. Moreover, PDGF is thought to play a role 
in a variety of pathological phenomena, such as cancer, fibrosis and atherosclerosis. PDGF is expressed as a dimer 
of A and/or B chains, the precursors of which are encoded by two single copy genes. Although the PDGF genes are 
expressed coordinately in a number of cell types, they are independently expressed in a majority of cell types. The 
expression of either PDGF gene can be affected by very diverse extracellular stimuli and the type of response is 
dependent on the cell type that is exposed to the stimulus. Expression of the PDGF chains can be modulated at every
imaginable level: by regulating accessibility of the transcription start site, by varying the transcription initiation rate, 
by using alternative transcription start sites, by alternative splicing, by using alternative polyadenylation signals, 
by varying mRNA decay rates, by regulating efficiency of translation, by protein modification, and by regulating 
secretion. Even upon secretion, the activity of PDGF can be modulated by non-specific or specific PDGF- binding 
proteins. This review provides an overview of the cell types in which the PDGF genes are expressed, of the factors 
that are known to affect the expression of PDGF, and of the various levels at which the expression of PDGF genes 
can be regulated.
Abbreviations: aFGF - acidic fibroblast growth factor; BAECs - bovine aortic endothelial cells; bFGF - basic 
fibroblast growth factor; BHK - baby hamster kidney; DAG - diacylglycerol, DH - DNase-I-hypersensitive; ECGF
- endothelial cells growth factor; EGF - epidermal growth factor; ER - endoplasmic reticulum; HKMECs - 
human kidney microvascular endothelial cells; HMECs - human mammary epithelial cells; HTLV - human T-cell 
leukemia virus; HUVECs - human umbilical vein endothelial cells; IFN - interferon; TL - interleukin; IPF - 
ideopathic pulmonary fibrosis; LDL - low density lipoprotein; LPS - lipopolysaccharides; PDGF- platelet-derived 
growth factor; PE - phenylephrine; PKC - protein kinase C; PNS - peripheral nervous system; RPE - cells, retinal 
pigment epithelial cells; SHS - nuclease SI hypersensitive site; SMCs - smooth muscle cells; SPARC - secreted 
protein, acidic and rich in cystein; SRE - serum response clement; SRF - serum response factor; SSV - simian 
sarcoma virus; TGF - transforming growth factor; TNF - tumor necrosis factor; TPA - 12-0-tetradecanoylphorbol 
13-actetate.
Introduction
Platelet-derived growth factor (PDGF) is an important 
polypeptide growth factor to which a variety of phys­
iological and pathological roles have been attributed.
Expression of PDGF is regulated in a cell type- and 
developmental-stage-specific manner and is subject to 
modulation by diverse extracellular stimuli. In a given 
cell type, regulation of PDGF expression may occur at 
the transcriptional level, the mRNA processing level,
2i
the translational level and/or the posttranslational lev­
el. This review intends to give an overview of the ceil 
types that express PDGF, the factors that affect PDGF 
expression and the mechanisms that are involved in 
regulation of PDGF expression.
achieved by activation of the corresponding n reccptor 
domain [351.
Platelet-derived growth factor
PDGF is first of all known for its activity as a serum 
mitogen for cultured smooth muscle cells (SMCs) [ 1 ], 
fibroblasts [2] and glial cells [3] and, secondly, as a 
chemo-attractant for SMCs [4] and fibroblasts [5j. In 
addition, it acts as a potent vasoconstrictor on rat aortic 
strips [6] and as a survival factor for cultured oligo­
dendrocytes and their precursors [7]. Whereas these 
activities seem to primarily serve normal physiologi­
cal processes, such as early development and wound 
healing, aberrant expression of PDGF may also play a 
role in the etiology of atherosclerosis (reviewed in [8]), 
fibrosis, neoplasia (reviewed in [9]) and desmoplasiu 
(reviewed in [10]),
PDGF is a collective term for the three dimeric 
disulfide bond-linked proteins that can be constitut­
ed out of type A and/or type B polypeptide chains 
(reviewed in [11]). The responsiveness of celts to 
PDGF is mediated by two specific receptors: the a 
receptor binds PDGF AA, AB and BB with high affin­
ity, whereas the ƒ3 receptor binds BB with high affinity 
and AB with low affinity and has negligible affinity for 
AA homodimers [12, 13]. The receptor specificity of 
the PDGF A and B chains is determined by very subtle 
structural differences. The change of only a few amino 
acids is sufficient to confer PDGF ¡3 receptor bind­
ing specificity to the PDGF A chain [14, 15], Bind­
ing of PDGF to its receptor induces dimerization and 
tyrosine-specific phosphorylation of the receptor [16- 
21], which initiates a signal transduction cascade and 
ultimately confers specific phenotypical changes to the 
responsive cell (reviewed in [10, 22]) . PDGF a  and 
/? receptor cDNA clones have been isolated [23-26] 
and are currently being used to unravel the mecha­
nistic pathways that are triggered by PDGF (reviewed 
in [22, 27, 28]). Whereas all three dimeric forms of 
PDGF are mitogenic and chemotactic [29, 30], only 
B chain homodimers transform NIH 3T3 fibroblasts 
with high efficiency [31-34]. This seems to be caused 
by differences in the signal transduction cascade that 
is initiated by a  and /3 receptors, as activation of the 
catalytic domain of the /? receptor in NIH 3T3 cells 
leads to 17-fold higher transforming activity than is
PDGF genes and proteins
PDGF was originally purified from human platelets and 
characterized as a cationic 3()-kI)a protein, consist­
ing of 14-kDa and 17-kDa disulfide-linked polypep­
tide chains (36, 371. Klucidation of their amino acid 
sequence revealed that it consists of two homologous 
polypeptide chains, the A and B chains [3K|. 'The dis­
covery that the PDGF B chain is the human hoinologue 
of the transforming proloin p2Nv of simian sarcoma 
virus (SSV) |39-4I | enabled the rapid isolation of the 
human c-sislPDGF B gene, a single copy gene located 
on chromosome 22 (42-461. The complete structure 
of the human PDGF B gene transcription unit was 
determined by el)NA cloning, nuclease SI mapping 
and primer extension. Seven exons spanning approx­
imately 22 kb give rise to a 3.5-kb mRNA, a large 
part of which consists of nontranslated sequences. A 
1022-bases long leader and a 1625-bases long trailer 
Hank a 723-bases long open reading frame. The loca­
tion of the transcriptional promoter was confirmed by 
the presence of a consensus TATA box sequence at 
30 bp upstream of the transcription start site [47, 4K| 
and by demonstrating its activity in a transient reporter 
gene assay [49, 50|. The first human PDGF A cDNA 
clone was isolated much later than its B chain coun­
terpart [511 and shortly thereafter the PDGF A chain 
gene was isolated and characterized. It is a single copy 
gene located on chromosome 7 |511 and, similar to the 
B chain gene, contains seven exons spanning approx­
imately 22 kb [52, 53|. The transcription start site 
was localized at approximately 36 bp downstream of a 
TATA box by nuclease SI and primer extension map­
ping 153, 541. The promoter was shown to he active in 
an />} vitro transcription assay and a transient reporter 
gene assay [541.
The availability of PDGF A and B cDNA clones 
enabled a detailed analysis of the structure/function 
relationship and of the processing of the correspond­
ing polypeptides (reviewed in 111, 55)). Whereas the 
B chain has higher transforming activity, the A chain 
is much more efficiently secreted |34|. PDGF A/B 
chimeras were used to map a membrane retention sig­
nal to amino acids 212-226 of the B chain. An anal­
ogous region is present in the A chain, hut normal­
ly subject to proteolytic cleavage 156, 57|. PDGF B 
residues 105-144 are responsible for/i receptor inter­
a
3action |56|. Newly synthesized PIXIF A and B chain 
precursors dimerize and undergo N-glyeosylation and 
proteolytic processing in (he endoplasmic reticulum 
(BR) and Golgi system. 30-kDa PDGF AA, AB and 
BB dimers are secreted via exocytosis, but the major 
part of PDGF BB is generated by additional proteoly­
sis in the Cioigi system and is expressed as a 24-kDa 
BB homodimer that remains membrane associated or 
is degraded in lysosomes |58 02), As PDGF was also 
detected in the cell nucleus, it may act via hitherto 
unknown mechanisms |03, M\.
Table /. Normal human cell types that arc capable o f PPGF 
expression
Sites of expression of PDGF
PDGF is expressed in a broad but speciiic subset of cell 
types and in a developmental stage-speciiic manner, 
The current idea is that its major function is in wound 
healing (reviewed in |(>5, M|) and early development. 
Upon deregulation it may play a role in the etiology of 
certain cancers and of atherosclerosis. Several normal 
cell types express PIXiF in culture and/or in situ (most 
of them are listed in Table I). In nearly every cell 
type the expression of PDGF can be modulated by 
extracellular stimuli, which allows the cell to adapt the 
production of PI X IF to changes in its environment.
Endothelial cells
Cultured vascular endothelial cells were among Ihe 
lirst normal cells found to secrete PDGF 167J and 
express PIXIF A and B mRNA |K7 891. As they 
lack PDGF receptors, expression of PIXiF has been 
thought to act in a paracrine way on connective tissue 
cells during development* maintenance and repair of 
the vasculature. The discovery that endothelial cells 
from microvessels express PIXit; receptors in culture 
and in situ led to the hypothesis that Pl)Crl; may also 
have an angiogenic function (90 92|. Co-expression 
of PDGF B and PIXiF /i receptor was also observed 
in proliferating vaseularendothelial cells of hyperplas­
tic capillaries within gliomas in situ, which suggests 
an autocrine role in vascularization of tumors [93 95|. 
Recently, PIXiF A and B and PiXrlwr receptor were
vessels in situ 1961. Thus, the capacity of autocrine 
growth stimulation via PIX.5F receptors may be a gen­
eral property of vascular endothelial cells.
Several factors have been shown to affect expres­
sion of PIXiF in endothelial cells (summarized
Cell type PDGF References
Vascular endothelial cells A, B 1671
Vascular smooth muscle cells A, B m\
Megakaryocytes/platelets A, B [69, 701
Monocytes, macrophages A, B [71, 721
Placental eytotrophobhists A, B [73|
Oocyte, blastocyst A 174, 75 J
Kidney mesangial cells A, B 176|
Fibroblasts A, B [771
Neurons A, H [7H|
Astrocytes A |7*>-8 J j
Skeletal myoblasts A |82|
titems eiulunkUmim/myometrium A, B |K3, H4|
Mammary epithelial cells A, B |K5j
Retinal pigment epithelial cells A. B ]X(i|
Tttbfr 2 .  Overview of I'adors dial modulate expression of
PDGF in vascular endothelial cells
^ * 1 «  a j i V i ,  H|LS it j á i ‘i[^~i~i~i r» i. i*> m . t t i B I  I ^  | áj l
Factor I ¿fleet Referentes
V  r 4 • V s *  *4  • h. mi^ i  Ç < <<r«f ■> t*' a  j ,  . j  f n * 1# ** i^>f
( ’alluring PD G FB  1 |H7|
Differentiation PD G FB  1 |07|
F t’GF PDGF A/B 1 |0H|
'i’hrombin VDOV' B Î |*W-1«3|
TCÏI-7J PDGF A/B 1 IW--Í03I
Forskolin (cAMP j ) PDGF A/B [ 11(H), 101, 1031
LD!, PDGF j 1 U)4-I()f>l
TNF p d g f  i 1107, l()K|
Bacterial endotoxin PDGF j 1 !(>'>!
LPS PDGF 1 | I I0 |
11. K 1 1 , 0 p d g f  | [10K. 1 1 0 . I i l|
hvav PDGF\[ 1 > 121
aFGF PDGF A Î | lll|
IFN PIXiF* 1 |I(W, 1 I0 |
1 typoxia PDGFB 1 111.11
Ih O iAi PD G FB  [ II I4|
Shear stress PDGF* A/B 1 J115, lib )
t «««< >|
in Table 2). isolated human umbilical
vein endothelial cells (HUVKCs) and bovine aortic 
endothelial cells (BARCs) express PDGF B mRNA, 
but the expression level increases strongly upon pro­
liferation in vitro |H7). Vice versa, withdrawal of 
endothelial cell growth factor (15CGF) from the cul­
ture medium of HUVKCs inhibits their proliferation 
and triggers their organization into tubular structures, 
which is accompanied by a strong decrease in PDGF B 
mRNA content (971. PDGF A and B mRNA levels
4are differentially affected by ECGF [981. Thrombin 
and transforming growth factor-/;? (TGF-/i) stimulate 
expression of PDGF by vascular endothelial cells, but 
apparently through different mechanisms. Thrombin 
may stimulate PDGF secretion at the posttranslational 
level [99]. In addition, both factors increase the tran­
scription rate of the PDGF B gene, but do not ailect 
the PDGF B mRNA half-life (70-90 min in human 
kidney microvascular endothelial cells (HKMECs)) 
[100-103], TGF-/3 also stimulates transcription of the 
PDGF A gene [100, 101, 103], The effect of throm­
bin is mimicked by phorbol ester suggesting that it 
acts through protein kinase C (PKC) [117], where­
as TGF-/3 acts independently of PKC [102]. Elevated 
cAMP levels (induced by forskolin) block the expres­
sion of PDGF A and B mRNA and inhibit the effect 
of thrombin and TGF-/3 on PDGF B mRNA expres­
sion, but not of TGF-/3 on PDGF A mRNA induction 
[100, 101, 103]. The thrombin-mediated increase in 
PDGF production by human aortic endothelial cells 
was shown to be dependent on Na+—H+-exchange and 
on G proteins, whereas the thrombin-mediated increase 
in PDGF A and B mRNA levels appeared to be inde­
pendent of Na+-H+-exchange [118], The thrombin 
stimulated production of PDGF is inhibited at the tran­
scriptional level by 3-deazaadenosine, which possibly 
acts via inhibition of S-adenosylhomocysteine hydro­
lase. This may result in accumulation of S-adenosyi 
homocysteine, a potent inhibitor of certain transmethy­
lation reactions [119]. Oxidized low density lipopro­
tein (LDL) and fish oil suppress the production of 
PDGF-like proteins by vascular endothelial cells, prob­
ably at the posttranscriptional level [ 104-106],
Several other factors were reported to stimulate 
PDGF mRNA and/or protein expression, such as tumor 
necrosis factor (TNF) [107, 108], bacterial endotoxin 
[109], 1 ipopolysaccharides (LPS) [110], interleukin-1 
(IL-1) [108, 110] and IL-6 [108, 111]. Basic fibrob­
last growth factor (bFGF) reversibly downregulates 
expression of PDGF B mRNA and secretion of PDGF 
by HUVECs [112], Acidic fibroblast growth factor 
(aFGF) transiently stimulates PDGF A gene transcrip­
tion and PDGF secretion, but does not affect the B 
gene [111]. The half-life of PDGF A and B mRNA 
in quiescent HUVECs (2.4 and 1.8 h, respectively) is 
not affected by aFGF [ 120]. Interferon-gamma (IFN-7 ) 
suppresses PDGF A and B mRNA levels and release of 
PDGF-like proteins in vascular endothelial cells [ 108, 
110]. Hypoxic conditions (0-3% oxygen environment) 
reversibly stimulate PDGF B gene transcription in cul­
tured HUVECs [113].H20 2 induces fourfold increased
PDGF B mRNA levels in cultured bovine pulmonary 
artery endothelial cells 1114]. Finally, physiological 
shear stress was reported to stimulate PDGF A and 
B mRNA levels in cultured endothelial cells, possi­
bly through PKC [I 15, 116|. in contrast, Mitsumata 
et al. 1121] found that the PDGF B mRNA level was 
induced by shear stress via a PKC independent mech­
anism, whereas the PDGF A mRNA level was not 
affected. Stimulation of PDGF B by shear stress is at 
the transcriptional level and a shear-stress-responsive 
element was mapped in the PDGF' B gene promoter 
by reporter gene analysis and gel shift assays 1122 ). 
Conflicting data were published by other investiga­
tors, which showed that in BAHCs shear stress reduced 
PDGF B mRNA levels by 4-fold 11231.
Smooth muscle cells
Expression of PDGF by vascular smooth muscle cells 
(SMCs) is developmentally regulated. Cultured aor­
tic SMCs from rat pups secrete al least 60«fold more 
PDGF than SMCs from adult rats [68, I24|. Prolonged 
culture triggers the adult rated Is to change from a con­
tractile to a synthetic phenotype, which is accompanied 
by the expression of PDGF 1125|. SMCs derived from 
injured rat arteries also show a synthetic phenotype 
[126|. PDGF A and B mRNA arc expressed at simi­
lar low levels in intact aortas from newborn and adult 
rats. Upon culturing, PDGF B mRNA accumulates 
in passaged newborn but not adult rat SMCs, where­
as PDGF A mRNA is found in comparable amounts in 
cells from both groups. PDGF B mRNA in newborn rat 
cells is shortlived, whereas PDGF A mRNA is more 
stable [82, 124, 127|, Cultured adult rat SMCs also 
express PDGF receptors and secrete PDGF upon expo­
sure to PDGF itself 1127|. Thus, PDGF may act both 
in an autocrine and a paracrine way on SMCs. Normal 
blood vessel walls have only a low cell turnover. There­
fore, it was suggested that PDGF A and B mRNA, 
which are present in situ in the tunica media and the 
tunica adventitia, respectively, play a nonmitogenic 
maintenance role in the normal vessel wall 1128|.
Expression of PDGF in SMCs is also associated 
with pathological conditions. PDGF and PDGF recep­
tor are expressed at specific times and places in injured 
carotid artery, which suggests a role in regulating arte­
rial wo u n d rep a i r [ 129 ]. PDG F ex p res s i o n 1 eve I s we re 
found to be elevated in atheroma and atherosclerotic 
plaques compared with normal arteries, which sug­
gests that PDGF may play a paracrine or autocrine
5Table J. Overview tii' factors (hut modulate expression 
of P IX iF  in viiscul.ir smoolh muscle cells
I mic tor Flieet References
A jl»c P IX JF I |()K, 124)
Culturing P IX iF  B | | K2, 124, 127]
PIXiF P IX iF  j 1127|
Angiotensin U PIXiF A | 1 1351
7C,Vf‘i PIXiF A |
Uric aciti PlX.iF A | 1 1371
Throinhiiwv PIX iF A | 1138, i:v;|
Dexamethasoue PIXiF A | 1140|
Serum PIX iF A | 1141|
Phorbol ester PIXIF’ A t IW H
aFCiF PIX iF A | 11411
TNFn PIX iF A ( 11411
I.M . PJXiF A ( 1142, I43|
Phenylephrine PIX iF A/H I |I*I4|
4  t  ‘  ^  '  I  A  > ' *w U * I
role in the etiology of atherosclerosis (130 I32|. How­
ever, a direct causal role of PIXit; in atherosclerosis 
has thusfar never been proven. Within the plaques, 
PDGF A inRNA expression correlates with SMCs, 
whereas PDGF B mRNA and protein are predomi­
nantly expressed in macrophages 1128, 133). Hlevat- 
ed levels of P1)GI; A mRNA and of the transcription 
factor Spl, a putative activator of the PDGF A gene, 
were found in SMCs of spontaneously hypertensive 
rats compared with normotensiveeontro! rats, suggest­
ing that high blood pressure-induced hypertensive vas­
cular hypertrophy is mediated by an autocrine PIXiF 
loop 1134).
Analogous to vascular endothelial cells, PDGF 
expression in SMCs is also affected by diverse fac­
tors (summarized in Table 3). Angiotensin II induces 
PDGF A mRNA and PDGF4 protein expression in cul­
tured quiescent rat aortic SMCs 1135J. Angiotensin
II was demonstrated to specilically induce expression 
of an alternatively spliced PDGF A mRNA species in 
cultured rabbit aortic SMCs |I45|. TC]F-/i, uric acid 
and thrombitwv promote the proliferation of vascular 
SMCs via induction of PDGF’ A mRNA and protein 
expression, thus creating an autocrine loop 1136-1391. 
Dexamelhasone inhibits the thrombin-induced induc­
tion of PDGF A secretion and the constitutive expres­
sion of PDGF A at the transcriptional level in SMCs 
I40|. PDGF* A mRNA levels in cultured human vascu­
lar SMCs are also stimulated by serum, phorbol ester, 
aFGF, TNFVv [1411, oxidized DDL 1142] and the n- 
adrenergic agonist phenylephrine (PH) [ 143|. PH also
induces a transient 10-fold increase in PDGF B mRNA 
content in rat thoracic aorta [144]. Similar to vascular 
endothelial cells, vascular SMCs respond to mechani­
cal strain by production of growth factors among which 
PDGF AA and BB. In addition, the strain induces 
increased proliferation of the SMCs, which can be part­
ly neutralized by anti-PDGF antibodies. Thus strain- 
induced proliferation may act via an autocrine PDGF 
loop [144],
Blood cells
Except in the cells of the vascular walls, PDGF1 is also 
present in several types of blood ceils, in accordance 
with its putative role in wound healing. PDGF is stored 
within a-granules of platelets, from which it is released 
during the clotting process [69|. PDGF from human 
platelets consists of AA, AB and BB dimers [ 146-1481, 
whereas PDGF from porcine platelets consists solely of 
BB homodimcrs [ I49|, Blood platelets are small cyto­
plasmic particles that lack a transcriptional machinery. 
The PDGF that they contain is synthesized in bone 
marrow megakaryocytes, from which the platelets are 
derived. Indeed, PDGF was detected by immunofluo­
rescence in cultured human megakaryocytie colonies 
170) and PDGF B mRNA in isolated human bone 
marrow megakaryocytes [ 150). Megakaryocytes form 
only a minor population of the bone marrow cells 
and therefore have been difficult to study. Phorbol 
ester treatment of the human hematopoietic stem cell 
line K562 was found to induce megakaryoblastic dif­
ferentiation, which is accompanied by PDGF A and 
B mRNA expression and secretion of PDGF. The 
induction of PDGF B gene expression by phorbol 
ester is regulated at the transcriptional level [ 1511, At 
present, phorbol ester treated K562 cells arc general­
ly accepted as a model for bone marrow megakary­
ocytes 1152|. PDGF B but not PDGF A mRNA expres­
sion is also induced by sodium butyrate mediated cry- 
throid differentiation of K562 cells (153] and by phor­
bol ester mediated megakaryocytie differentiation of 
human erythroleukemia cell line HEL f 154].
PDGF’ A and B mRNA and PDGF protein are 
present in cultured human alveolar and peritoneal 
macrophages and in in vitro maturated or activated 
human monocytes [71, 72, 155, 156]. Human blood 
monocytes were found to secrete a PDGF-like mito­
gen resembling a monomer [ 1571. Human wound fluid 
contains PDGF-like peptides of 16-17 kDa and 34-36 
kDa (1581, which may thus correspond with monomer-
6ic and dimeric forms of PDGF. Oxidized LDL inhibits 
constitutive expression of PDGF B mRNA and protein 
by adherent cultures of human blood monocyte-derivcd 
macrophages. Oxidized LDL also attenuates LPS- 
induced PDGF B mRNA expression [159]. Enhanced 
expression of PDGF by macrophages was also found in 
association with pathological conditions. E.g., alveolar 
macrophages from patients with idiopathic pulmonary 
fibrosis (ÏPF) release four times more PDGF [ 160] and 
express threefold higher PDGF A and B mRNA lev­
els than alveolar macrophages derived from healthy 
persons [161]. Expression of PDGF B mRNA and of 
PDGF was also detected in situ in epithelial cells and 
macrophages of lungs from patients with IPF, where 
it may play a role in the abnormal fibroblast prolif­
eration and collagen production [162]. Transcription 
of the PDGF B gene in broncho alveolar mononuclear 
cells from patients with pulmonary sarcoidosis 11631 
or with autoimmune diseases with lung involvement 
is enhanced compared with cells derived from healthy 
persons [164]. In vitro maturation of monocytes to 
macrophages is accompanied by increased transcrip­
tion rates of the PDGF A and B genes. This results 
in increased PDGF B mRNA and protein but does 
not affect PDGF A mRNA levels, suggesting that 
PDGF A expression is regulated at the posttranscrip- 
tional level. Similarly, alveolar macrophages transcribe 
the PDGF A and B genes at similar rates while the 
steady state PDGF B mRNA and protein levels are
5-fold higher than those of the PDGF A chain. Where­
as resting monocytes express only the short PDGF A 
mRNA that lacks the exon 6-derived sequences, in vit­
ro maturated monocytes and alveolar macrophages 
express both the short and the long PDGF A mRNA 
species [165].
Analogous to the megakaryocytic differentiation of 
K562 cells, some leukemia celi lines can be induced to 
differentiate along the monocyte/macrophage pathway.
In addition, various factors have been shown to affect
PDGF mRNA and protein expression in these cell er major role for PDGF is in early vertebrate devel- 
ünes (summarized in Table 4). Phorbol ester induces opinent, already from the earliest stages onwards, 
monocytic differentiation of human myeloid leukemia PDGF A mRNA and protein arc expressed in mouse
cell lines HL-60 and U-937, which is accompanied blastocysts and the mRNA is expressed as a mater- 
by expression of PDGF A and B mRNA and synthe­
sis and secretion of PDGF-like proteins. In contrast,
PDGF A and B mRNA are not expressed in untreated 
HL-60 cells or in HL-60 cells induced to differentiate 
along the granulocyte pathway [153, 166, 167], Phor­
bol ester treatment of THP-1 monocytic leukemia cells 
induces only PDGF A mRNA expression. Cyclohex- 
imide induces PDGF B mRNA expression in mono­
cytes, but whether the PDGF B gene is transcriptionally 
active in resting monocytes was not examined [ I67|. 
IFN-7 mediated monocytic differentiation of HL-60 
cells is not accompanied by PDGF B mRNA expres­
sion 11731. IFN-7 suppresses PDGF mRNA and pro­
tein production by phorbol ester activated TI IP-1 cells, 
but does not affect PDGF mRNA stability. IFN-7 also 
inhibits PDGF mRNA expression in monocyte-derived 
macrophages cultured in the presence of GM-CSF 
|174|. TNF-rv and dexamethasone induce expression 
of, respectively, PDGF A and B mRNA in HL-60 cells 
1153, 1681. TCW-fl stimulates PDGF’ A mRNA expres­
sion in U-937 and T-eeII leukemia MOLT-4 cells and 
also induces PDGF A mRNA expression in HL-60 and 
Jurkat T-cell leukemia cells. TGF-/V mediated induc­
tion is stable in U-937 and transient in IIL-60 cells 
and is accompanied by secretion of PDGF-like protein 
169]. Hypoxic macrophages were recently shown lo 
synthesize and secrete PDGF’, which could subsequent“ 
ly stimulate the proliferation of hypoxic endothelial 
cells, thus contributing to angiogenesis under hypoxic 
conditions [ 1701.
Although PDGF is not expressed in normal lym­
phocytes, HTLV-infected lymphocytes were shown lo 
express PDGF A and B mRNA |I7L 1721. Recent­
ly, undifferentiated murine erythroleukemia cells were 
found to express PDGF protein and induction of ery- 
throid differentiation was accompanied by more than 
15-fold increased PDGF expression levels. A simi­
lar increase of PDGF expression levels was found in 
the mouse spleen in vivo upon stimulation of normal 
erythropoiesis by phenylhydrazine or erythropoietin 
175].
Early development
In the adult vertebrate, expression of PDGF is closely 
associated with tissue maintenance and repair. Anoth-
nai transcript in unfertilized ovulated oocytes |74| 
and in Xenopus eggs |75|. PDGF' A mRNA is 
also detectable in bovine preimplanlation embryos 
1176], where PDGF stimulates development of bovine 
embryos during the fourth cell cycle 11771. By using 
inhibitors of the PDGF signalling pathway» it was 
recently shown that PDGF plays a direct role in gastru- 
lation of sea urchin embryos [ 1781 and Xenopus lae-
7Table 4, lectors iluil modulai
<%r % »  v»<*> * . « y. »■ » «  . ,  t « fc ^ é — m i M f p  i n j ^ y .  -... ^
(VU type
^  »*> • • >■ <*«»«.«■» I* I •>. I » ■«» I I*  ÉÉ^.a-..«-«^ * A ^ mm n ■
K562 erylhroleukemia 
K562 erylhroleukemia 
t II il, erydtroleukemia 
Maeropl litres 
Monocytes
111, 60 myeloid leukemia
IMM7 myeloid leukemia 
T IIIM  monoeylic lenkemii 
Mt>nocyies
111 ,60  myeloid leukemia 
HL 60 myeloid leukemia 
U l>37 myeloid leukemia 
MOI ,T 4 T cell leukemia 
UK (il) myeloid leukemia 
Jurkui ‘f  eelI leukemia
Macrophages
Lymphocytes
; expression of PDGF in hluod
• * ~ r r i ---- i "  itn M i n i ^  i r  i --- ■-• ____ -  ________________  _________- _______
Factor Li fleet
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vis embryos [ I7()|. Additional evidence (or a role for 
P1XIF in early Xenopus development was provided by 
in situ hybridization studies* which showed expression 
of PIXiF A mRNA in neural ectoderm, otic vesicle 
and pharyngeal endoderm, and of PIXiF n receptor 
mRNA in neural crest cells |IK()|. PIXiF A and rv 
receptors are coexpressed in preimplantation mouse 
embryos and* thus» may play an autocrine role | INI |. 
Following implantation, PIXiF A is mainly expressed 
in the epithelium, whereas the receptor is expressed in 
the mesenchyme, which suggests a paracrine activity 
across cell layers | INI, 1H2|. PIXiF is also expressed 
at later stages of vertebrate development. Marly studies 
already demonstrated expression of PIXiF B mRNA 
during embryonic and fetal development of the mouse 
I S31, PIXIF* A but not B mRNA is expressed in 6.5- 
N.5 day mouse embryonic and postembryonie tissues 
and both n and ¡i receptor mRNA are expressed in 
early mouse embryos | IH4|. In day 16 embryonic rat, 
PDGF and its receptor can be detected in central and 
peripheral nervous system, gastrointestinal and gas- 
trourinary system, respiratory tract, muscle and carti­
lage. In day IN embryonic rat, the expression peaks 
and is detectable in almost all organs, whereas after 
day IN expression is especially seen in stomach, kid­
ney, liver, pancreas and sex cords |IN5|. Recently, 
expression of the PDGF // receptor was examined 
in sifu during organogenesis in the mouse embryo. The 
PIXiF* ji receptor was first detected in the periaortic
mesenchyme and, later, particularly in derivatives of 
the primitive gut, Expression was exceptionally high 
in mesenchyme directly supporting epithelia of many 
organs, such as trachea and intestine. High expression 
levels were also detected in endothelium of small blood 
vessels and in vascular structures, sue!) as hyaloid 
plexus and choroid plexus. In large blood vessels, 
the receptor was expressed in mesenchyme surround- 
ing the epithelium 11N6|, The importance of PDGF B 
and the PDGF fi receptor in mouse embryonic devel­
opment has recently been proven by the analysis of 
null-mutant mice 1187, INN|. PDGF B null mutants 
die perinalally from fatal bleedings and suffer from 
erythoblastosis, macrocytic anemia and thrombocy­
topenia. The bleedings may result from deficiencies 
in blood clotting, reduced platelet function or lack of 
function and integrity of the vascular wall. The mutant 
mice lack kidney mesangial cells and glomerular tufts. 
The heart and some large arteries are dilated, possibly 
due to the lack of vasoconstrictive activity of PIXiF 
1N7|. The PDGF/;/ receptor null mutant mice exhibit 
the same blood and kidney deficiencies as were found 
in the PDGF B null mutants and also die perinalally 
from fatal bleedings. Their major blood vessels and 
hearL appear normal, possibly because the role of the 
PIXiF ¡1 receptor can be partially compensated by the 
n receptor. Since the clotting capacity of the blood was 
not affected, the fatal bleeding may result from defects 
in the microvasculature 11 NN|.
8PDGF is also expressed during early development 
in humans. PDGF B and /3 receptor are detectable 
immunocytochemically during the development of 
glomeruli in human kidneys oi 54 to 105 days ges­
tational age. During early glomerulogcnesis, PDGF B 
expressed in the epithelium may act in a paracrine 
way, whereas later PDGF B and the fi receptor arc 
coexpressed in mesangial cells and, thus, may play an 
autocrine role [189]. Normal human fetal kidney cells 
secrete PDGF and express PDGF A mRNA [ 190].
A role for PDGF in embryonic development has 
also been studied in tumor cell models, Murine and 
human embryonal carcinoma cell lines were tound 
to express PDGF A mRNA and secrete PDGF f 184, 
191-193]. TGF-/3 induces PDGF B mRNA and PDGF 
secretion in mouse embryo-derived AKR-2B cells, 
which may play a role in an autocrine loop [194|. 
Human teratocarcinoma stem cell line Tera-2 express­
es high levels of PDGF A blit not B mRNA and 
the PDGF A mRNA level is markedly reduced upon 
retinoic acid mediated endodermal or neuroectodermal 
differentiation [195]. Undifferentiated murine terato­
carcinoma cell line F9 also expresses PDGF A mRNA 
and protein and much lower levels of PDGF B mRNA. 
Exposure of F9 cells to retinoic acid induces differ­
entiation to endoderm-Iike cells, which is accompa­
nied by cessation of PDGF A production, but not of 
PDGF A mRNA expression. Whereas in undifferenti­
ated F9 cells the PDGF A mRNA is present in polyri­
bosomes, in differentiated cells the mRNA colocalizes 
with the free ribosome fraction, which indicates that 
the PDGF A mRNA is not translated in differentiated 
cells [196].
A role for PDGF in placental development was 
proposed upon the discovery that PDGF B mRNA is 
expressed in human placental cytotrophoblasts in situ. 
As cytotrophoblasts also express PDGF receptors, an 
autocrine mechanism in placental development was 
suggested [73, 197]. Expression of PDGF by the pla­
centa is under apparent developmental control, with a 
peak during the second trimester [73, 198], Cocxprcs- 
sion of PDGF B and ¡3 type receptor was also observed 
in microcapillary endothelial cells of first trimester 
human placentae, suggesting that an autocrine loop 
may play a role in placental angiogenesis as well [ 199].
Kidney mesangial cells
Cultured human glomerular mesangial cells release 
PDGF and express PDGF A and B mRNA. They
also respond mitogenieally to PDGF suggesting an 
autocrine role in mesangial cell proliferation [76, 200, 
2011. Moreover, PDGF AB and BB induce synthesis 
of PDGF A and B mRNA in mesangial cells [202]. 
A normal monkey kidney cell line secretes PDGF 
and expresses PDGF B mRNA, which is stimulated 
by TOP~/i and ADP (2031. PDGF' B mRNA is also 
expressed in baby hamster kidney (BI-IK) cells upon 
transfection with foreign DNA [2<)4|. Thrombin |205|, 
phosphaiidic acid |206| and endolhelin 12071 stimulate 
expression of PDGF mRNA and phorbol ester stim­
ulates PDGF A gene transcription in human mesan­
gial cells |208|. The thrombin-mediated induction of 
PDGF B gene expression in mesangial cells was recent­
ly shown to be dependent on PKC a |209|. Several 
factors that are mitogenic for mesangial cells, such as 
serum, PDGF, FGF, TGIwv, bFGF and TNIwv stim­
ulate PDGF mRNA expression. TGF-/^ also induces
PDGF mRNA expression, but inhibits proliferation of 
mesangial cells [210, 2111. In a ral model of mesan­
gial proliferative glomerulonephritis, PDGF B mRNA 
and protein are expressed in situ. Moreover, PIXiF A 
and B mRNA levels are increased in glomerular RNA, 
which correlates with mesangial cell proliferation. In 
addition, PDGF /i receptor mRNA and protein are 
increased in glomerular nephritis |212, 2 13|. Recently, 
rat visceral glomerular epithelial cells were also shown 
to express PDGF B mRNA and protein in culture and 
in situ, but PDGF (1 receptor mRNA or protein could 
not be detected |2l4|.
Fibroblasts
Normally, PDGF mRNA and protein are not expressed 
in cultured human dermal fibroblasts [87, 89|, Howev­
er, transient expression of PDGF' A mRNA and protein 
occurs when cultured dermal fibroblasts are exposed 
to PDGF', FGF [771, TGF~/i [215, 2l6|, TNF |2l7| 
or IF-1 |2I8|, It was suggested that these factors 
stimulate proliferation of fibroblasts through autocrine 
production of PDGF’ A. Recently it was shown that 
the PDGF B induced PDGF A production is reduced 
in fibroblasts from old donors compared with fibrob­
lasts derived from embryonic and neonatal donors, 
suggesting developmental stage-specific regulation of 
PDGF or PDGF receptor expression [2I9|, Follow­
ing cutaneous injury in pigs, PDGF' B and PDGF ¡1 
receptor mRNA and protein are reversibly coexpressed 
in situ in skin epithelial cells and in fibroblasts, where­
as PDGF is not dcteetably expressed in tmwounded
9skin in situ [220|. This suggests tluil expression of 
PDGF in fibroblasts plays a rote in wound healing 
in vivo. PDGF A mRNA and/or protein expression in 
fibroblasts was also observed under certain pathologi­
cal conditions, e.g. in a strain of Hutchinson- CJilford 
(progeria) syndrome fibroblasts |221] and in primary 
cultures of breast libroblasts derived from benign and 
malignant lesions of breast tumors |222). PDGF' A is 
also expressed in cultured rat lung libroblasts 1223], 
and, recently, expression of PDGF A and B and of 
the PDGF ¡i receptor was detected in fetal rat lung 
libroblasts. The expression of PDGF* A was constant­
ly low during late gestation and did not significantly 
change subsequently, whereas the expression of the 
PIXiF B chain was maximal at embryonic day 19 and 
decreased sharply thereafter 12241. The expression lev­
el of PIXIF4 A mRNA and protein increases upon expo­
sure of cultured rat lung libroblasts it) asbestos, which 
may cause autocrine growth stimulation. Huts, PDGF* 
A production may play a role in asbestos-induced pul­
monary fibrosis 12251.
Neural tissues
Rat brain expresses PIXiF* mRNA throughout glio- 
genesis |KI j and rat brain neurons express PIXiF' /I 
receptors in vitro and in vivo, Moreover, primary rat 
brain ceils can be mitogenically stimulated by PIXiF 
|226|, Whereas (he transcription rales of the A and 
B chain genes in the rat central nervous system are 
similar, (he mRNA level of the B chain is I (Mold 
lower (lum that of the A chain, suggesting differences 
in mRNA half-life |227[. PIXiF' may play a role in 
regeneration of nerves, as PIXiF' A and B mRNA and 
PIXiF’ protein are expressed in facial neurons upon 
facial nerve axotomy in rats |228|. PDGF* A mRNA 
and protein are also expressed at high levels in situ 
in neurons of embryonic and adult mouse, where they 
may regulate proliferation and differentiation of glial 
cells [78, 229). Specific immunostaining for PDGF B 
chains was found in primate neurons, principal den­
drites, some axons and terminals throughout the brain; 
in the dorsal horn of the spinal chord and in the posteri­
or pituitary. PDGF A and B and PI X iF receptor mRNA 
are expressed throughout the brain and posterior pitu­
itary; a transgenic model in which the chloramphenicol 
aeetyltransferase (CAT) reporter gene was driven by 
the PDGF* B promoter revealed preferential expression 
within neuronal cell bodies in the cortex, hypoeampus 
and cerebellum. Thus* PDGF’ may act as a neuronal
regulatory agent [230]. Recently, PDGF B-related 
mitogenic activity and 2.6 kb and 3.5 kb PDGF B
mRNA species were detected in ubiquitous neurons 
of mature rat brain in situ, especially in hippocampal 
pyramidal cells. Since these neurons do also express 
PDGF receptors, PDGF may act as an autocrine and/or 
paracrine neuronal regulatory or trophic agent [2311. 
In human brain tissue, PDGF A and PDGF [3 recep­
tor mRNA are detectable, but PDGF B mRNA is not 
detectably expressed [951.
PDGF is also expressed in neonatal rat peripheral 
nervous system (PNS), Schwann cells and neurons. In 
adult rat, myelinated nerve libers express low PDGF 
levels, whereas unmyelinated nerve libers express high 
levels. PDGF1 a and ft receptors are also expressed in 
neonatal PNS. In adult rut* both receptors genes are 
expressed in unmyelinated nerves [232|. In cultures of 
rat neurons and astroglial cells PDGF and its recep­
tors are coexpressed, suggesting an autocrine role in
neuronal difierentiation [233J.
PDGF A is secreted by type-1 astrocytes present in 
the developing rat optic nerve and stimulates in vitro 
proliferation of C)-2A progenitor cells, which express 
predominantly PDGF rv receptors (79-81, 234, 235). 
Axonal electrical activity may control production 
and/or release of PDGF [236|. After rat embryonic 
day 16, PDGF <\ receptor mRNA is expressed in a 
subset of glial cells, predominantly ceils of the Q-2A 
lineage, but not by neurons 12371. Recently, v-crhA, 
a mutated thyroid hormone receptor, was shown to 
induce PDGF B gene expression in glial cells, which 
may play a role in the development of gliomas [238].
Other cell types
Most studies on PDGF7 have described its expression 
in the vasculature, in blood cells, during early devel­
opment, in kidney and 111 neural tissues. However, 
there have hecn several reports of PDGF expression 
in other tissues, which are summmari/ed in this sec­
tion. PDGF A expression was detected in myoblast cell 
lines, primary rat skeletal myoblasts and developing rat 
crude muscle tissue |82, 239|. PDGF B (two mRNA 
species) is expressed in human uterus endometrium 
and myometrium samples (83|. PDGF A mRNA is 
also expressed in the uterus and the expression level 
increases in myometrial SMC in situ during pregnan­
cy and diminishes again during the puerperium, This 
implicates a role for PDGF in uterine expansion during 
pregnancy |84|.
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Cultured normal human mammary epithelial cells 
(HMECs) express PDGF A mRNA and protein but 
little or no PDGF B mRNA. TGF-ft, which inhibits 
growth of HMECs, induces a 20-40-fold increase ol 
PDGF B mRNA, a 2-fold increase of PDGF A mRNA 
and a 2-3-fold increase of PDGF secretion. Sodium 
butyrate and phorbol ester, which also inhibit growth 
of HMECs, do not affect PDGF expression [85],
PDGF A and B mRNA are expressed in rat lung 
and, upon exposure to hyperoxia (87% oxygen), the 
PDGF A mRNA level increases and transcription of 
the PDGF B gene increases by up to 10-fold, Elevated 
PDGF expression preceeds a proliferative response of 
micro vascular adventitial fibroblasts, precursor SMCs 
and epithelial cells [240, 241].
Cultured human retinal pigment epithelial (RPE) 
cells secrete PDGF [86] and express PDGF A and B 
and PDGF a  and ft receptor mRNA. Phorbol ester and 
thrombin induce a 16-20-fold increase of the PDGF B 
mRNA level in RPE cells [242], PDGF A mRNA was 
also detected in situ in rat RPE cells as well as in 
retinal neurons and ganglion cells. PDGF A protein 
was detectable in ganglion neurons of the mouse reti­
na and PDGF a  receptor mRNA in retinal astrocytes, 
Therefore, a short range paracrine role for PDGF A in 
the retina was suggested [243]. Recent studies indicat­
ed that the PDGF receptors on RPE cells cultured in 
serum-free medium are autophosphorylated and that 
suramin blocks the autophosphorylation. Moreover, 
anti-PDGF antibodies inhibit the growth of RPE cells 
in serum-free medium. Together, these studies strong­
ly suggest that RPE cells use an autocrine PDGF loop 
for serum-independent growth [244], PDGF B and ft 
receptor mRNA were detected in the vascular systems 
of the eye, probably in the capillary endothelial cells 
[243]. As PDGF BB also induces proliferation of rabbit 
retina capillary endothelial cells, an autocrine PDGF 
pathway may play a significant role in angiogenesis
[245]. PDGF B and the PDGF ft receptor are coex­
pressed in many cells of proliferative human retinal 
membranes, where they could contribute to pathogen­
esis of different proliferative retinopathies by paracrine 
or autocrine stimulation of cell migration and growth
[246]. Recently, PDGF a  receptors were identified in 
the peripheral epithelium of the chicken lens, where 
PDGF may control lens growth [247].
Human primary osteoblastic bone cells and cul­
tured fetal osteoblast cells express PDGF A [248,249] 
and the human cells also express PDGF a and ft recep­
tors, raising the possibility of autocrine growth stimula­
tion [248]. TGF-/31 increases PDGF A mRNA and pro­
tein expression by 3-6-foId in the fetal osteoblast cells 
[249]. \L~\ft stimulates proliferation of rabbit articu­
lar chondrocytes and induces synthesis and release of 
PDGF The \L-\ft effect is specific for PDGF AA and 
acts at the transcriptional level. TG\'-ft inhibits IL-i/j 
induction of PDGF A [2501.
Cultured human keratinocytes express PDGF A 
and trace amounts of PDGF B mRNA and secrete 
PDGF AA protein. IL-la induces PDGF B expression, 
whereas TGF-/  ^ induces both PDGF A and B mRNA 
expression. PDGF AA and BB protein are also present 
in normal human epidermis in situ. PDGF receptor is 
not detectable in cultured keratinocytes or epidermis, 
which suggests that PDGF is not part of an autocrine 
loop in these cells |2511.
Recently, PDGF B mRNA was detected in Ley dig 
and Sertoli cells of the rat testis, and also PIXiF A 
mRNA was found in the Sertoli cells. As these cells do 
also express <\ and ft PDGF receptors, both paracrine 
and autocrine roles (or PDGF in the testis were sug­
gested |252f
Expression in transformed cells
Shortly after the identification of PDGF it was dis­
covered that certain human osteosarcoma and glioma 
cell lines secrete PDGF-like proteins, which led to 
the hypothesis that expression of PDGF may he asso­
ciated with the etiology of these cancers [253, 254|, 
The current idea is that PDGF may play an autocrine 
and/or paracrine role in Lumorigenesis dependent on 
whether a tumor cell coexpresses PDGF and its recep­
tor or whether it stimulates adjacent receptor express­
ing cells; through paracrine stimulation of connective 
tissue and blood vessels, PDGF’secreted by tumor cells 
may inducedesmoplasiaand angiogenesis. Indeed, sta­
ble transfection and expression of PDGF B in an origi­
nally PDGF B negative melanoma cell line induces the 
development of a vascular connective tissue stroma in 
subsequent xenografts |255|,
The list of tumor species that express PDGF is 
still increasing (see e.g. Table 5) and in some cas­
es the expression level was shown to be affected by 
extracellular factors. The expression level of PDGF 
may be an important parameter for its putative role 
in tumorigenesis: e.g. the level of PDGF B mRNA 
expression in 3T3 cells determines the acquisition of 
features of transformation in a dose-dependent man­
ner [3111. Glucocorticoids suppress the expression of 
PDGF A mRNA and protein by a rat hepatoma cell
t
Table 5. Expression of PDGF mRNA and protein and of PDGF receptor in transformed ceils 
in culture (C), in situ (S) or in tumor biopsies (Bi). not determined
Tumor species PDGF
mRNA
PDGF
protein
PDGF
receptor
References
Sarcoma (C) A,B — yes [256, 257]
Osteosarcoma (C) A,B yes yes [258-261]
Mesenchymal (C) — yes yes [2621
Glioma (C,S) A,B yes yes [94, 261, 263-265 J
Mouse neuroblastoma (C) B yes — [266)
Prostate carcinoma (C,S) A,B yes yes [267-269]
Glioblastoma (C,Bi,S) B yes — [93,256, 270, 2711
Fibrosarcoma (C,S) B yes — [270, 2721
Melanoma (C) A,B yes yes [261, 273-275)
Giant cell of bone (Bi) B — [276)
Mesothelioma (C) A,B yes — [277-281 ]
Nephroblastoma (C) A yes yes 1190]
Breast carcinoma (C,S) A,B yes no [282-286]
Lung carcinoma (C,S) A,B yes yes [285, 287-2901
Gastric carcinoma (C,Bi,S) A tB yes yes [285, 291-293
Ovarian carcinoma (C) A,B yes no [285]
Hepatoma (C) yes — yes [294]
Medulloblastoma (C) — yes — [295]
Colon adenocarcinoma (C) — yes — [296]
Astrocytoma (Bi,S) A,B yes yes [95, 297]
Meningioma (S,Bi) B yes yes [298-301]
Kaposi sarcoma (S) A,B _ yes [302]
Midgut carcinoid (S) yes yes yes [303]
Endocrine pancreatic (C,S) A,B yes yes [303, 304]
Neurinoma (Bi) B — — [301]
Choriocarcinoma (C,S) B — yes [305, 3061
Pancreatic adenocarcinoma (C,B) A,B yes yes [307]
SV40-transformed BHK (C) B — — [308, 309]
HSV-transformed 3T3 (C) A — — [310]
MoSV-transformed NRK (C) A ~ — [310]
line [312], whereas expression of PDGF by MCF-7 
cells is induced by 17/3-estradiol [283], PDGF A and 
B mRNA levels in cultured human pancreatic adeno­
carcinoma cells are stimulated by TNF-a and TNF-/3. 
Both inhibition of PKC by staurosporin and stimula­
tion of PKC by phorbol ester increases PDGF B mRNA 
levels [304], Phorbol ester, TGF-/3 and diacylglycerol 
(DAG) induce a transient increase of the transcription 
rate of the PDGF B gene in A172 cells, but phor­
bol ester and TGF-/3 use different signal transduction 
pathways [313]. An increase of the cellular cAMP lev­
el blocks PDGF B mRNA expression in some human 
glioma and osteosarcoma cell lines without affecting 
stability of PDGF B mRNA [314], PDGF stimulates 
PDGF A mRNA expression in cultured Kaposi’s sar­
coma derived cells [315]. Sodium butyrate inhibits 
growth and induces differentiation of F-98 rat glioma 
cells. The differentiation is accompanied by a signifi­
cant and irreversible increase of the PDGF B mRNA 
level, which is at least partly caused by an increase of 
the mRNA half-life from 40 to 100 min [316],
Regulation of PDGF expression
From the overview above one could get the impression 
that PDGF can be expressed in any cell type. How­
ever, the fact that aberrant expression of PDGF B in 
e.g. fibroblasts may lead to oncogenic transformation 
already implicates that the expression must be tightly
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regulated. Thusfar, the majority of research on regula­
tion of expression of PDGF has been descriptive. The 
molecular mechanisms that are involved in regulation 
of expression of the PDGF genes are only beginning to 
be understood. Since there are numerous manners in 
which the expression of the PDGF genes can be mod­
ulated, it is not surprising that these mechanisms have 
evolved into a highly complicated network.
Regulation of transcription rate
Transcription of the PDGF genes can be modulated by 
very diverse extracellular stimuli, such as mitogens, 
cytokines, tumor promoters, shear stress, uric acid and 
oxygen concentration (see above; reviewed in [317]). 
The response of the PDGF genes to these stimuli and 
the cell type- and develop mental-stage-dependent tran­
scription of the genes are mediated by the interaction 
between specific DNA elements in the PDGF genes 
and regulatory transcription factors, which trigger the 
transcriptional machinery. These regulatory DNA ele­
ments have been mapped in only a few cell types, 
whereas the transcription factors that interact with the 
elements and their link to second messenger pathways 
are largely unknown.
Given the fact that the PDGF A and B genes are 
often independently expressed, it is not surprising that 
their promoter sequences are not homologous. Actual­
ly, one of the few similarities is the presence of a TATA 
box at approximately 30 bp upstream of either gene. 
Fig. 1 gives an overview of regulatory DNA elements 
that have thus far been identified in the promoters of 
the PDGF A and B chain genes.
Regulation of PDGF B gene transcription
Immediately upon the cloning of PDGF B exon 1, it 
was shown that the first 386 bp upstream of the tran­
scription start site are sufficient for promoter activity 
in HeLa cells [49]. The first cell type in which the 
PDGF B promoter was analysed in more detail was 
the megakaryocytic cell line K562. Upon treatment 
with phorbol ester these cells differentiate towards 
megakaryocytes. This is accompanied by a more than 
200-fold increase in PDGF B mRNA level, which is 
dependent on protein synthesis. By reporter gene anal­
ysis it was shown that the first 72 bp upstream of 
the transcription start site are essential for minimal 
promoter activity in uninduced K562 cells. A region
between —101 bp and -58 bp appeared to be essential 
for TPA inducibility. Deletion of the region between 
-105 bp and -85 bp led to a three-fold decrease of 
TPA inducibility, and deletion of the region between 
-105 bp and -41 bp reduced promoter activity to 
background levels. By means of gel retardation exper­
iments nuclear factors from K562 cells were shown to 
bind specifically to the region between —103 bp and 
-60 bp and the binding activity increased upon TPA 
treatment [322]. In a recent linker scanning analysis, 
the region between —64 bp and —39 bp appeared to be 
essential for TPA inducibility of the PDGF B promoter
[323], This is supported by combined in vivo footprint 
and deletion mutant analysis of the PDGF B promot­
er in phorbol ester-treated megakaryocytic K562 cells, 
which showed that the region between —61 bp and 
—54 bp is bound by a potent transcriptional activator, 
In a similar way it was shown that the region between 
—64 bp and —60 bp is bound by a weak transcriptional 
activator required for basal promoter activity in unin­
duced K562 cells and in HeLa, PC3 and JEG-3 cells
[324], In the nucleus, sites of DNA-protein interac­
tions are usually located in nucleosome-free regions, 
which can be identified by their hypersensitivity to 
DNase I. The DNase-I-hypersensitive (DH) site at the 
PDGF B promoter in TPA-treated K562 cells extends 
from —90 bp to +60 bp, indicating that only one nucle- 
osome is displaced. The first 112 bp upstream of the 
PDGF B transcription start site are sufficient for a 15- 
30-fold increase in PDGF B promoter activity during 
phorbol ester mediated megakaryocytic differentiation 
of K562 cells [328], whereas DH sites far upstream of 
the gene coincide with transcriptional enhancers that 
together with the promoter could result in a 100-1000- 
fold increase in promoter activity [329].
By reporter gene analysis of deletion mutants a 
region located between —292 bp and —278 bp was 
shown to contain a positive transcription regulatory 
element that is required for full promoter activity in 
HOS osteosarcoma cells and A 172 glioblastoma cells. 
Further deletion up to -99 bp reduced promoter activi­
ty to background levels in these cells. In the same study 
it was demonstrated that the first 1.4 kb upstream of 
PDGF B gene harbours a binding site for the HTLV-I 
and HTLV-II derived transcription activating tat pro­
teins, but the exact location of this binding site has 
thusfar not been described [325].
Transcription regulatory elements were also 
mapped in PDGF B intron 1. In cultured primary 
placental cytotrophoblasts, DH sites were localized at 
1.6 kb, 3.8 kb, and 4.3 kb downstream of the transcrip-
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Figure 1. Transcription regulatory elements in the promoters and immediate upstream regions of the human PDGF A and B chain genes. Black
bars indicate the positions of the regulatory elements relative to the transcription initiation site.
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tion start site, whereas these sites were not found in 
placental fibroblasts. In JEG-3 choriocarcinoma cells, 
DH sites were found at 1.6 kb and 3.8 kb downstream 
of the start site, and in U2-OS osteosarcoma cells a 
single site at +6.3 kb was found. Fragments that con­
tained either the hypersensitive site at +1.6 kb or at 
+3.8 kb enhanced promoter activity respectively by 
4-fold and 8-fold in JEG-3 cells, whereas the entire 
PDGF B intron I was found to enhance activity of the 
PDGF B promoter by 26~foId in JEG-3 cells [305]. 
This is in contrast with the observation that the DH 
sites at +1.6 kb and +3.8 kb act as potent silencers of 
the PDGF B promoter in JEG-3 cells and also in K562 
cells [328]. These conflicting results can be explained 
by the recent discovery that the DH site at +3.8 kb coin­
cides with an alternative transcription initiation site 
[330]. Thus, in the reporter gene constructs described 
by Franklin et al. [305] and Dirks et al. [328] two pro­
moters were present in one single plasmid, which may 
have affected the activity of either promoter. A frag­
ment that contained the DH sites at +6.3 kb silenced 
the PDGF B promoter activity by 2-3-fold in U2-OS 
cells [305]. The relative activity of the PDGF B pro­
moter in HeLa cells and PC3 prostate carcinoma cells 
is not significantly different, although the PC3 cells 
express a much higher level of PDGF B mRNA than 
the HeLa cells. DH sites at —9.9 kb and +25 kb con­
tain enhancers that may explain the increased activity 
of the PDGF B promoter in PC3 cells compared with 
HeLa cells [328,329].
By reporter gene analysis of deletion mutants and 
site directed mutants it was shown that an ETS-like 
sequence between -80 bp and -70 bp and an AP- 
1-like sequence between -92 bp and -85 bp rela­
tive to the transcription start site are important for 
activity of the PDGF B promoter in vascular endothe­
lial cells. Synthetic oligonucleotides containing either 
the ETS-like element or the AP-l-like element inter­
act with proteins present in endothelial cell nuclear 
extracts, but recombinant AP-1 and ETS-like pro­
tein GAB Pa do not interact with the PDGF B pro­
moter in vitro. Mutagenesis of the Sp 1 -like CCAC- 
CC sequence between -61 bp and -56 bp reduced 
activity of the PDGF B promoter in endothelial cells 
by twofold. The —61/—56 sequence interacts with a 
nuclear protein from endothelial cell and with purified 
Spl, suggesting that an Sp 1 -like protein is involved 
in regulation of transcription of the PDGF B gene in 
vascular endothelial cells [326]. By linker scanning 
analysis of the PDGF B promoter in U2-OS osteosar­
coma cells, regions at -63/-44 bp, - 102/-95 bp and
—244/—203 bp were identified as important positive 
regulatory elements. The —63/—44 element increased 
activity of a heterologous TATA box by 5-fold. By 
site directed mutagenesis the CCACCC sequence at 
—61/—56 bp was shown to be essential for the activity 
of the element and found to interact with an Spl-like 
factor present in U2-OS nuclear extracts [327]. Recent­
ly, a shear-stress response element that mediates the 
increase in PDGF B gene expression upon exposure 
of vascular endothelial cells to fluid shear stress [122] 
was shown to interact in vitro with NF-acB p50-p65 
heterodimers. Moreover, p50-p65 was shown to acti­
vate PDGF B shear-stress response element-dependent 
reporter gene activity in cotransfection experiments, 
suggesting that NF-kB may play a direct role in fluid 
shear stress-induced activity of the PDGF B gene in 
vascular endothelial cells [331].
The PDGF B gene is also subject to negative tran­
scription regulation, as e.g. cultured dermal fibroblasts 
contain a transcriptional activator directed toward the 
PDGF B promoter, but do not express the endogenous 
PDGF B gene. The PDGF B promoter is unmethylated 
and not located within a DH site in fibroblasts [324, 
328]. No DNA-protein interactions could be detected 
by in vivo footprint analysis of the PDGF B promoter 
in fibroblasts [324]. In addition, a silencer could not 
be found within a region that extends from — 12 kb 
to +25 kb relative to the transcription start site in 
fibroblasts [328, 329]. We must therefore conclude 
that the inhibition of transcription of the PDGF B gene 
in fibroblasts is mediated by a mechanism that has not 
yet been unraveled. One of the few possibilities that 
remain is that the accessibility of the PDGF B pro­
moter for the transcriptional activator is blocked by 
histones, as a result of specific nucleosome phasing. A 
DH site that is located immediately downstream of the 
PDGF B promoter in fibroblasts might play a direct 
role in the phasing of nucleosomes [328]. By analysis 
of somatic cell hybrids between PDGF B expressing 
melanoma cells and hamster fibroblasts it was shown 
that the negative regulation of the PDGF B chain is 
probably mediated by a trans-acting factor [332]. It 
would be interesting to test whether this factor acts by 
introducing changes in the chromatin structure at the 
PDGF B gene promoter.
Regulation of PDGF A gene transcription
In contrast to the PDGF B promoter, the PDGF A pro­
moter is exceptionally G/C-rich [52,53]. Eight consen­
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sus binding sites for transcription factor Sp 1 are located 
within the first kb upstream of the transcription start 
site. The region between -447 bp and +387 bp has
promoter activity in an in vitro transcription assay using 
HeLa nuclear extract and in a reporter gene assay using 
RD rhabdomyosarcoma cells [54], A region between 
-69 bp and —60 bp, immediately downstream of a 13- 
bp oligo(dG) stretch exhibits supercoiling dependent 
nuclease-Sl-hypersensitivity in vitro. it contains three 
Spl consensus binding sites and is required for full 
activity of the PDGF A promoter in HeLa cells. A syn­
thetic oligonucleotide complementary to the nuclease 
S1 hypersensitive site (SHS) of the PDGF A promoter 
protects this site against nuclease S1 and reduces pro­
moter activity in a transient reporter gene assay [318, 
333]. Another supercoiling dependent SHS is located 
immediately upstream of the 13-bp oligo(dG) stretch 
between —96 bp and -90 bp. By gel shift analysis 
the -96/—90 and —69/—60 regions were shown to 
interact specifically with proteins present in nuclear 
extracts from RD cells. Reporter gene analysis of dele­
tion mutants demonstrated that the first 72 bp upstream 
of the transcription start site are already sufficient for 
promoter activity in RD cells and that the —69/—60 
region is important for activity [333], Spl-like ele­
ments between -82 bp and -40 bp are also required 
for full activity of the PDGF A promoter in African 
green monkey (BSC-1) cells [320]. The first 600 bp of 
the PDGF A promoter contain at least six consensus 
binding sites for transcription factors EGR-1 and the 
Wilms’ tumor associated WTL Coexpression of EGR- 
i and a PDGF A promoter/reporter gene construct indi­
cated that EGR-1 can either activate or repress activity 
of the PDGF A promoter dependent on the cell type 
examined. W T1 was shown to interact in vitro with 
the PDGF A promoter and abolishes its activity in 
a reporter gene assay. As PDGF A is overexpressed 
in certain Wilms’ tumors, this raises the possibility 
that deregulation of WT1 or PDGF A may contribute 
to the etiology of this tumor [319, 334]. The repres­
sion of PDGF A promoter activity by WT1 requires 
the presence of WT1-binding sites both upstream and 
downstream of the transcription start site. The pres­
ence of either an upstream or a downstream binding 
site results in WTI mediated transcriptional activation. 
Different domains of WTI are involved in transcrip­
tional repression and activation [335]. Deletion mutant 
analysis in HeLa cells demonstrated that a negative 
transcription regulatory element is located upstream of 
-618 bp, probably between —1.9 kb and —0.9 kb 
[321], A similar reporter gene analysis in African
green monkey (BSC-1) cells identified two negative 
elements between -1029 bp and -880 bp and between
— 1800 bp and —1029 bp [320]. Positive elements were 
mapped in HeLa cells between —558 bp and —447 bp 
and downstream of -150 bp. By DNase I footprint 
analysis the region between -89 bp and —33 bp was 
found to interact in vitro with purified Sp 1. A serum 
response element (SRE) located between —477 bp and 
—468 bp appeared to be required for growth factor 
mediated induction of PDGF A promoter activity in 
human foreskin fibroblasts. The SRE interacts in vit­
ro with a serum response factor- (SRF-) like protein 
present in HeLa nuclear ectract [321]. The SRE also 
coincides with a supercoiling dependent SHS. The 
noncoding strand of the SRE was found to interact 
specifically with a single-stranded DNA-binding pro­
tein present in a HeLa cell nuclear extract [336], Serum 
response elements that stimulate transcription of the 
PDGF A gene were also found between —135 and 
—223 bp, whereas elements that down-regulate expres­
sion of the gene during serum starvation were localized 
between -223 and -416 bp [337]. Recently, a protein 
present in nuclear extracts of human mesangial cells 
was found to bind in vitro to region -102/-82 of the 
PDGF A gene promoter. The abundance of the pro­
tein increases during phorbol ester-mediated increase 
of PDGF A gene transcription, but its nature is still 
unknown [338]. A supercoiling dependent SHS located 
between —495 bp and —484 bp relative to the transcrip­
tion start site of the PDGF A gene interacts specifically 
with proteins present in nuclear extracts from HeLa 
and A 172 cells and slightly increases the activity of 
a heterologous promoter [339]. A supercoiling depen­
dent SHS located between +50 bp and +67 bp rela­
tive to the transcription start site interacts in vitro with 
purified transcription factors Spl and EGR-1 [340]. 
Finally, a supercoiling dependent SHS was detected in 
a 147-nucleotides long region in the first intron of the 
PDGF A gene. By reporter gene analysis the intron ele­
ment was shown to silence the PDGF A promoter and 
a heterologous promoter in HeLa cells. The element 
specifically interacts with a protein present in nuclear 
extracts from HeLa cells [341]. In vitro methylation 
of the PDGF A gene promoter resulted in strongly 
reduced activity in a transient reporter gene assay in 
HeLa cells. DNA methylation might thus cause the low 
PDGF A mRNA level in these cells. Unfortunately, the 
methylation state of the endogenous PDGF A promoter 
in HeLa cells was not examined. Purified Spl, which 
is thought to play a role in regulation of transcription
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of the PDGF A gene, binds to the PDGF A promoter 
irrespective of its méthylation State [342].
from this upstream ATG would yield a polypeptide of 
118 amino acids. Except in macrophages, the alter­
native PDGF A transcript is also expressed in fetal, 
newborn and adult brain and kidney [346].
Regulation of mRNA stability
Alternative transcription initiation sites
Small PDGF B mRNA species are induced by treat­
ment of vascular endothelial cells with cyclohex-
imide and TGF-/31. A 2.8-kb transcript initiates 15 
nucleotides upstream of the translation start site, result from differences in transcription rate of the gene,
whereas a 3.0-kb transcript initiates 200 nucleotides rather than from differences in mRNA stability [103,
further upstream. The expression of truncated PDGF B 151]. The PDGF B mRNA half-life varies roughly
mRNA species may provide a way to escape from the from 1-3,5 h in rat smooth muscle cells [ 124], vascular
mRNA
potent translation inhibitory activity of the exon 1- 
derived 5' untranslated sequence [343], The expres­
sion level of a 2.5-kb PDGF B mRNA expressed 
in melanoma cell line WM115 also highly increases 
by treatment with cycloheximide [332], whereas the 
expression level of a 2.7-kb PDGF B mRNA in rat 
lung increases upon exposure to hypoxic conditions 
[344]. Whereas the 2.8-kb and 3.0-kb PDGF B mRNA 
species expressed in endothelial cells seem to have an 
intact PDGF B open reading frame, JEG-3 choriocar­
cinoma cells express a 2.6-kb PDGF B mRNA species 
that initiates at an alternative promoter located within 
intron 1 and lacks the code for the signal peptide of the 
PDGF B chain precursor. The resulting protein product 
may be targeted to the nucleus due to the presence of a 
nuclear localization signal encoded by PDGF B exon 
6 [330]. A 2.6 kb PDGF B mRNA species was also 
found in normal mature rat brain, but the exact nature 
of this transcript was not described [231].
Nuclease S1 and reporter gene analysis demonstrat­
ed that the PDGF A gene uses two promoters. The 
regular transcription start site is located approximately 
35 bp downstream of the TATA box, whereas the alter­
native initiation site is located 470 bp downstream of 
the first site, but still 380 bp upstream of the translation 
start site [345]. A novel PDGF A cDNA clone isolat­
ed from a rat macrophage cDNA library lacks exon 
6-derived sequences and has a 588-nucleotides coding 
region that is 91% identical with the human PDGF A 
code. The 79 nucleotides immediately upstream of the 
PDGF A open reading frame are 92% identical in the 
human and the rat mRNA, whereas the similarity in the 
remaining part of the 5' untranslated sequence is less 
than 30%. It was hypothesized that the rat PDGF A 
mRNA could be initiated at an alternative promoter. 
The 5' untranslated sequence of the rat cDNA clone 
contains an ATG codon that is not in frame with the 
PDGF A open reading frame. Translation initiation
endothelial cells [102, 120], bladder carcinoma cell 
line T24 [271], glioblastoma cells [271, 313, 314], 
PC3 prostate carcinoma cells and phorbol ester treated 
K562 cells [328].
Regulation of translation
The 1 -kb long leader of the 3.5-kb PDGF B transcript 
can inhibit translation in vitro and in reporter gene 
assays up to 40-fold [50, 325, 347], The leader is 
highly GC-rich and contains three small open reading 
frames. The open reading frames are not important 
for the translation inhibitory capacity of the leader, as 
mutation of the AUGs does not affect the production of 
PDGF B chains [348]. Regions 1-651 and 475-1022 
are equally potent inhibitors of translation as the entire 
PDGF B leader sequence. Either region contains a C- 
rich element and sequences that are capable of forming 
strong stem-loop structures [348]. The highly GC-rich 
140-nucleotides long sequence immediately upstream 
of the PDGF B open reading frame is nearly as effec­
tive an inhibitor as the entire leader. The inhibitory 
activity is partly relieved by deletion of nucleotides 
154-378 or 398-475. The PDGF B leader also sig­
nificantly reduces the transforming efficiency of the 
PDGF B gene in NIH 3T3 cells [50, 325, 347]. The 
translation inhibitory activity of the PDGF B leader is 
temporarily relieved during megakaryocytic differenti­
ation of K562 cells, when transcription of the PDGF B 
gene is also strongly induced. The 179-nucleotides 
long sequence immediately upstream of the PDGF B 
open reading frame was shown to be important for 
relief of translation repression [349]. Cultured primate 
aortic SMCs express PDGF A and B mRNA but do 
not express or secrete PDGF-Iike protein, suggesting 
negative regulation at the translational level [350].
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The PDGF A 5' untranslated sequence contains 
three ATG codons [53], the function of which is 
unknown. In a recent study the region between +99 bp 
and +184 bp relative to the PDGF A transcription 
start site, which lacks an ATG codon, was shown to 
inhibit translation in RD rhabdomyosarcoma cells, but 
the inhibitory effect could be overcome by sequences 
located between +184 bp and +338 bp [351 ].
Alternative polyadenylation sites
The PDGF A gene uses three alternative polyadenyla­
tion sites. In combination with the regular transcription 
start site these yield mRNA species of 2.3 kb, 2,8 kb 
and 3.6 kb. When combined with the alternative tran­
scription start site, transcripts of 1.8 kb, 2.4 kb and 
3,2 kb are generated. Since these PDGF A mRNA 
species can also be subjected to alternative splicing of 
exon-6, the theoretical number of different PDGF A 
mRNA species increases to twelve [345]. Human pap­
illary carcinoma cell line NPA expresses a monomeric 
PDGF-like protein and a 1.4-kb PDGF B mRNA that 
hybridizes with 5' cDNA probes but not with 3' probes, 
which could result from alternative polyadenylation
[352].
Alternative splicing
Alternative splicing of PDGF mRNA (reviewed in
[353]) was first discovered when PDGF A cDNA 
clones were isolated from a human glioma cell line that 
represent two alternatively spliced transcript species 
differing by exon 6-encoded 69 bases at the 3' part 
of the open reading frame; normal HUVECs express 
a short PDGF A chain precursor that lacks the 15 
C-terminal highly basic amino acids encoded by the 
larger exon 6-containing glioma cDNA [53, 98, 354], 
Both the short and the long PDGF A mRNA species 
are expressed in a variety of normal tissues and trans­
formed cells and in diverse mammalian species [281, 
355, 356]. In contrast with the short PDGF A chain, 
which is efficiently secreted, the long version of the 
A chain remains predominantly cell associated. Sev­
eral lines of evidence suggest that the exon 6-encoded 
basic C-terminus associates with heparan-suJphate pro­
teoglycans within the cell membrane and the cellular 
matrix. The PDGF B chain contains a homologous 
region in its C-terminus that determines its association 
with the cell membrane and cellular matrix. Alternative 
splicing of exon 6 may thus be a mechanism to regu­
late the formation of secreted or cell-associated forms
of PDGF A [357-360], A synthetic peptide that cor­
responds with the 18-amino-acids-long hydrophilic C- 
terminus inhibits the specific binding of growth factors 
to cells bearing their respective receptors and inhibits 
serum induced mitosis in cultured fibroblasts [361, 
362]. The alternatively spliced exon 6 of PDGF A 
also contains a nuclear targeting signal that is capable 
of targeting a non-secreted form of the PDGF A chain 
to the nucleus [363], By PCR analysis two transformed 
human cell lines were shown to express PDGF A tran­
scripts lacking exon 2-derived sequences, which gener­
ates truncated and non-functional polypeptides [364], 
Aberrant splicing was found to occur between a cryp­
tic splice donor site in the short PDGF A chain cDNA 
and a viral splice acceptor site present in a eukaryotic 
expression vector, which resulted in the synthesis of a 
non- secreted PDGF A chain [365]. A novel PDGF A 
chain cDNA clone (A3), which was generated by alter­
native splicing of a 110 bp segment, was isolated from 
a rabbit embryonic aorta cDNA library [145].
Alternative splicing of PDGF B mRNA was 
observed in a recombinant retrovirus that expresses 
the wildtype PDGF B chain and induces fibrosarco­
mas in mice. Proviruses derived from the tumors had 
lost a 149-bases sequence derived from exon 7, due 
to alternative splicing, Interestingly, an identical splice 
event is visible in the SSV genome, which suggests that 
these 149 bases are detrimental for retroviral expres­
sion or replication [366], The mouse PDGF B gene 
has the same exon-intron structure as the human gene. 
Their coding regions are 89% identical and the first 
120 nucleotides of the untranslated exon 7 are even 
94% identical, but are followed by a highly divergent 
sequence. It was hypothesized that this sequence could 
be involved in alternative splicing of exon 6, as is also 
observed for the PDGF A gene. An alternative PDGF B 
transcript that lacks exon 6 derived sequences has not 
yet been described [367].
Posttranslational regulation
It has become clear that a given cell type can quali­
tatively or quantitatively affect the expression of the 
PDGF chains at the transcriptional, mRNA processing 
and translational level. However, even after efficient 
transcription of a PDGF gene and translation of its 
mRNA, the amount and type of the PDGF protein to 
be expressed can still be determined at the posttransla­
tional level. PDGF purified from platelets consists as 
two polypeptides, PDGF-I and PDGF-II [368], which 
differ in carbohydrate composition [369]. The role of
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glycosylation in PDGF activity, processing and trans­
port is not clear, and glycosylation is probably not 
essential for one of these processes. Activity of PDGF 
released in vivo may be regulated by association with 
a2-macroglobulin, to which a large part of PDGF binds
reversibly [370-372].
Another protein that may regulate activity of PDGF 
is the extracellular glycoprotein SPARC (secreted pro­
tein, acidic and rich in cysteine). It binds specifically 
to PDGF AB and BB, but not to AA, and inhibits 
binding of PDGF AB and BB to the PDGF receptor. 
Therefore, it may regulate activity of specific dimer­
ic forms of PDGF [373]. Recent studies on vascular 
endothelial cells that had been stably transfected with 
a PDGF B expression vector provided evidence for 
yet another level of regulation. A major part of the 
PDGF B expressed by the transfectants remained asso­
ciated with the extracellular matrix. Thrombin induced 
a rapid release of PDGF B by selective proteolytic 
cleavage of the membrane associated PDGF precursor 
protein. In this way a cell can quickly respond to a 
sudden need for growth factor, even in the absence of 
mRNA and protein synthesis [374],
Conclusions and future aspects
Since its purification, some fifteen years ago, it has 
become clear that PDGF is a highly important polypep­
tide growth factor that plays an essential role during 
early vertebrate development and is associated with 
wound healing in the adult. PDGF acts via the binding 
to and the activation of specific high affinity cell sur­
face receptors. Both the PDGF A and B chain genes 
and the PDGF a and ¡3 receptor genes have been iso­
lated and characterized, which has enabled the detailed 
structural and functional analysis of their protein prod­
ucts. A broad range of cell types has been described 
that are capable of expressing either or both of the two 
PDGF genes, sometimes in a developmental stage- 
specific manner. Moreover, many factors have been 
identified that can modulate the expression (level) of 
PDGF in a given cell type. Finally, several pathological 
phenomena have been found associated with increased 
expression levels of PDGF.
Now that the place and time of expression of PDGF 
have largely been settled, research has focused more 
on the mechanistic aspects of PDGF expression. The 
signal transduction cascade that is initiated by acti­
vation of the PDGF receptors is rapidly being eluci­
dated. Knowledge of the molecular mechanisms that 
are involved in regulation of expression of the PDGF
genes is still limited, but rapidly accumulating. In prin­
ciple, the expression of PDGF genes can be modulated 
by regulating the initiation, the initiation rate or the 
initiation site of transcription, by alternative splicing, 
by alternative polyadenylation, by varying the mRNA 
stability, by regulation of translation efficiency and 
by regulation at the posttranslational level. In gener­
al, regulation at the transcription level has been found 
to play a decisive role in regulation of expression of 
PDGF per se. In a number of cell types the DNA ele­
ments that mediate transcription of PDGF genes have 
now been characterized, which will soon be followed 
by the isolation and characterization of the transcrip­
tion factors that bind to them. Identification of these 
transcription factors will enable one to elucidate the 
mechanisms that link the changes in the cells’ environ­
ment or developmental stage with the changes in the 
transcription rate of the PDGF genes. This is not only 
important for extending the fundamental insight in reg­
ulation of the PDGF genes in normal cells, but will also 
lead to a better understanding of the changes in PDGF 
expression under pathological conditions. Ultimately, 
this may lead to the development of novel strategies in 
the ongoing fight against disease.
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